TY - JOUR
AR - JICOA-2020-4-110
TI - ApoL6: A Novel Biomarker of Apoptotic and Necroptotic Activity in Evolving STsegment Myocardial Infarction in Man
AU - Chien-An, Andy Hu
AU - Siqin , Zhaorigetu
AU - W Sean , Davidson
AU - Warren , Laskey
JO - Journal of Integrative Cardiology Open Access
PY - 2020
DA - Mon 24, Aug 2020
SN - 2674-2489
DO - http://dx.doi.org/10.31487/j.JICOA.2020.04.10
UR - https://www.sciencerepository.org/apol6-a-novel-biomarker-of-apoptotic-activity-in-evolving-st_JICOA-2020-4-110 
KW - Apolipoprotein L6 (ApoL6), apoptosis, myocardial infarction, necroptosis
AB - We have previously demonstrated that apolipoprotein L6 (ApoL6) is a pro-death, phospholipid-binding,
BH3-only member of the Bcl-2 family. Ectopic expression of ApoL6 induces dichotomous cell death
phenotype involving both apoptosis and necroptosis in various cell types. In addition, ApoL6 initiates
inflammatory response that upregulates proinflammatory cytokines, such as IL-1β. In this study, we show
elevated levels of ApoL6 in the sera of the majority of ST-segment myocardial infarction (STEMI) patients
prior to reperfusion which is highly suggestive of the activation of apoptotic and/or necroptotic pathways in
ruptured plaque. Thus, ApoL6 could serve as a biomarker specific for inflammatory apoptotic and/or
necroptotic activity in STEMI, as well as other diseases.